

QIBA PET-Amyloid Biomarker Committee (BC) Call

Friday, September 13, 2019 at 9 AM CT

Call Summary

In attendance:

Dawn Matthews, MS (Co-chair)

Satoshi Minoshima, MD, PhD (Co-chair)

Anne Smith, PhD (Co-chair)

Nancy Obuchowski, PhD

John Sunderland, PhD

Jean-Luc Vanderheyden, PhD

RSNA

Joe Koudelik

Julie Lisiecki

Moderator: Dr. Smith

Approval of 07.12.2019 call summary

- The summary was approved as presented

Status of PET-Amyloid Profile Feasibility Questionnaire

- Mr. O'Donnell previously recommended a hands-on review of questions, in addition to interviewing users
- Breaking out the questions by actor and getting at least two sites to confirm participation is planned
 - There are 19 content items in the spreadsheet that refer to medical physicists
 - There are 40 content items for technologists
 - These questions are on separate tabs of the Excel-based checklist
- Ms. Matthews to send finalized checklist to Drs. Subramaniam and Sunderland for feasibility testing, as they volunteered to assess the PET-Amyloid questionnaire
 - The checklist and questionnaire will be sent to one more site, TBD
 - If it were to be more widely distributed, using SurveyMonkey for the questionnaire would be considered

Considerations for Technical Confirmation

- Dr. Sunderland discussed efforts to obtain new funding ideas for an FDG-PET clinical trial that is largely written
- Piggy-backing the FDG-PET test-retest study onto an existing pharma trial with these criteria:
 - Pharma must have a trial ready to go (soon)
 - Pharma must be committed to use the QIBA Profile
 - Pharma must be willing to cover the expense for the extra test-retest subjects
 - The test-retest study with a limited number of patients would need to meet the statistical endpoint
- Getting the Profile to [Stage 3: Technically Confirmed](#) is the current goal
 - Need to avoid a multi-year delay and push the Profile out into the community for utilization
 - Achieving Technically Confirmed was deemed a realistic goal for the Amyloid Profile
 - It is understood that due to limited resources, getting to the Claim Confirmed stage may not be achievable
- The next step will be publishing the Profile as technically confirmed
- More details regarding advancing through Profile stages can be found on the QIBA wiki here:
 - <http://qibawiki.rsna.org/index.php/Process>
 - http://qibawiki.rsna.org/index.php/Technical_Confirmation_Process#Planning
- Once completed, the PET-Amyloid Profile to be promoted as a finished product

QIBA NM Modality Poster for RSNA 2019

- The focus of the posters this year has been changed to appeal to the broader radiology community and demonstrate the value of QIBA and QI, and how they can enhance clinical practice and clinical trials
- Each modality will have one poster, which will be a combined effort across BCs
- The posters should be visually appealing, with more images and less text

- Emphasis should be on the impact of QI and showcasing the work of QIBA; these are not “technical reports” as was the case in the past
- Specific to PET-Amyloid:
 - Value of the DRO might be a good example for the PET-Amyloid section of the poster
 - Articles where quantitative Amyloid is being used might be helpful
 - Efficacy of the Profile and statistical work
 - Any trials that were functionally aligned with the QIBA methods could be useful examples
 - If referencing an article, tying it back to the QIBA Profile was recommended to show the impact or utility of the QIBA Profile, e.g. some text for repeatability
 - Time and money saved by companies due to QI may also be helpful to note
- Dr. Sunderland volunteered to be the poster coordinator; any text or images can be sent to him, preferably in the PowerPoint template: john-sunderland@uiowa.edu
- Dr. Smith to follow up with Dr. Kinahan regarding DRO updates

Next Steps

- Sites to be consulted regarding subject motion, subject positioning and transaxial uniformity
 - Ms. Matthews to contact Drs. Subramaniam and Wahl
- Actor-specific checklists to be distributed to participating sites
- Dr. Smith (with a cc to Dr. Minoshima and Ms. Matthews), to request a DRO update from Dr. Kinahan

QIBA Nuclear Medicine Schedule:

 The next scheduled QIBA calls will be as follows at **9 am CT** unless otherwise noted:

9/18	NM Poster Dev Call @ 10 am CT
9/27	NM Leadership – TBD
10/04	FDG-PET BC
10/08	SPECT TC ^{99m} BC @ 2 pm CT
10/11	PET Amyloid BC
10/25	NM Leadership – TBD
11/08	Print -ready copy deadline for QIBA CC posters
11/15	NM Q4 Coordinating Committee